| Trial ID: | L1556 |
| Source ID: | NCT06660524
|
| Associated Drug: |
Sevelamer
|
| Title: |
Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Degenerative Heart Valve Disease|Heart Valve Calcification|Chronic Kidney Disease(CKD)|Calcium-Phosphorus Metabolism Disorders
|
| Interventions: |
DRUG: Sevelamer|DRUG: Calcium carbonate
|
| Outcome Measures: |
Primary: The change of valve calcification score on CT scan from baseline to 1 year of treatment., The change of valve calcification score on CT scan from baseline to 1 year of treatment., from baseline to 1 year of treatment | Secondary: major cardiovascular events, The composite endpoint of major cardiovascular events includes hospitalization or outpatient/emergency department visits due to heart failure; cardiovascular death; undergoing interventional/surgical valve surgery; and non-fatal myocardial infarction., from baseline to 1 year of treatment
|
| Sponsor/Collaborators: |
Sponsor: China National Center for Cardiovascular Diseases
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
196
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-03-01
|
| Completion Date: |
2025-12
|
| Results First Posted: |
|
| Last Update Posted: |
2024-10-28
|
| Locations: |
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science, Beijing, Beijing, 100037, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06660524
|
